Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and the Risk of Acute Pancreatitis: A...

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Epidemiology

Background:

• Conflicting evidence exists regarding the association between Renin-Angiotensin-Aldosterone System (RAAS) medications and acute pancreatitis risk.
• Observational studies have yielded inconsistent results on the safety of RAAS inhibitors concerning pancreatitis.

Purpose of the Study:

• To conduct a meta-analysis evaluating the risk of acute pancreatitis in patients using angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs).
• To synthesize existing observational data to clarify the pancreatitis risk associated with specific RAAS-acting drug classes.

Main Methods:

• A systematic search of PubMed and Embase was performed to identify relevant observational studies.
• A random-effects model was employed to pool odds ratios (ORs), with sensitivity analyses and alternative meta-analysis methods (Knapp-Hartung, Bayesian) used to assess robustness.
• Eleven observational studies were included in the meta-analysis.

Main Results:

• ACE inhibitors were associated with an increased risk of acute pancreatitis (OR 1.33; 95% CI 1.12-1.58).
• ARBs did not show a significant association with increased pancreatitis risk (OR 0.82; 95% CI 0.80-0.83).
• Incidence rates were 0.98 cases/1000 person-years for ACE inhibitors and 0.71 cases/1000 person-years for ARBs.

Conclusions:

• ACE inhibitors appear to elevate the risk of acute pancreatitis, whereas ARBs do not demonstrate this association.
• Healthcare professionals should consider the potential for pancreatitis when prescribing ACE inhibitors.
• Further research may be warranted to explore the mechanisms underlying this differential risk.